

# Muscle and not neuronal biomarkers correlate with severity of muscular atrophy

Neurology

92, e1205-e1211

DOI: [10.1212/wnl.00000000000007097](https://doi.org/10.1212/wnl.00000000000007097)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. <i>Journal of Neurology</i> , 2020, 267, 36-44.	3.6	47
3	Plasma pNfH levels differentiate SBMA from ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 215-217.	1.9	11
4	Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. <i>Molecular Neurodegeneration</i> , 2020, 15, 58.	10.8	68
5	Harmony Lost: Cell-Cell Communication at the Neuromuscular Junction in Motor Neuron Disease. <i>Trends in Neurosciences</i> , 2020, 43, 709-724.	8.6	17
6	Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment. <i>Current Opinion in Neurology</i> , 2020, 33, 629-634.	3.6	9
7	Kennedy's disease: an under-recognized motor neuron disorder. <i>Acta Neurologica Belgica</i> , 2020, 120, 1289-1295.	1.1	2
8	Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1085-1091.	1.9	28
9	Deterioration of muscle force and contractile characteristics are early pathological events in spinal and bulbar muscular atrophy mice. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	8
10	The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 90.	2.7	31
12	Update on Biomarkers in Spinal Muscular Atrophy. <i>Biomarker Insights</i> , 2021, 16, 117727192110356.	2.5	27
13	Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis. <i>Translational Neurodegeneration</i> , 2021, 10, 3.	8.0	15
14	Creatine kinase in the diagnosis and prognostic prediction of amyotrophic lateral sclerosis: a retrospective case-control study. <i>Neural Regeneration Research</i> , 2021, 16, 591.	3.0	9
15	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1049-1063.	3.7	29
17	Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. <i>Journal of Neurology</i> , 2021, 268, 3835-3844.	3.6	14
18	Evaluation of peripherin in biofluids of patients with motor neuron diseases. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1750-1754.	3.7	11
19	Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. <i>Frontiers in Neurology</i> , 2020, 11, 586610.	2.4	4
21	Spinal and bulbar muscular atrophy as a multisystem disease with motor neuron and muscle involvement: literature review and a case report. <i>Nervno-Myshechnye Bolezni</i> , 2020, 10, 81-87.	0.4	0
22	Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. <i>Nature Neuroscience</i> , 2021, 24, 1534-1541.	14.8	57

#	ARTICLE	IF	CITATIONS
23	Using genetic testing to diagnose Kennedy's disease: a case report and literature review. American Journal of Translational Research (discontinued), 2021, 13, 7412-7417.	0.0	0
24	Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy. Frontiers in Neurology, 2022, 13, 793937.	2.4	4
25	A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies. Frontiers in Neurology, 0, 13, .	2.4	6
26	Skeletal Muscle Pathogenesis in Polyglutamine Diseases. Cells, 2022, 11, 2105.	4.1	2
27	Neuromuscular junction pathology is correlated with differential motor unit vulnerability in spinal and bulbar muscular atrophy. Acta Neuropathologica Communications, 2022, 10, .	5.2	10
28	Clinical Features of Female Carriers and Prodromal Male Patients With Spinal and Bulbar Muscular Atrophy. Neurology, 2023, 100, .	1.1	0
29	The role of ubiquitination in spinal and bulbar muscular atrophy. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	7
30	Genotype and clinical phenotype analysis of a Family with Kennedy disease. Medicine (United States), 2023, 102, e33502.	1.0	0
31	Defective excitation-contraction coupling and mitochondrial respiration precede mitochondrial Ca <sup>2+</sup> accumulation in spinobulbar muscular atrophy skeletal muscle. Nature Communications, 2023, 14, .	12.8	8
32	Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study. Brain and Behavior, 0, , .	2.2	2
33	X-linked SBMA model mice display relevant non-neurological phenotypes and their expression of mutant androgen receptor protein in motor neurons is not required for neuromuscular disease. Acta Neuropathologica Communications, 2023, 11, .	5.2	0
34	Biomarkers in 5q-associated spinal muscular atrophy—a narrative review. Journal of Neurology, 2023, 270, 4157-4178.	3.6	2
35	Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS. Life, 2023, 13, 1301.	2.4	2
36	An overview on androgen-mediated actions in skeletal muscle and adipose tissue. Steroids, 2023, 199, 109306.	1.8	2
37	The value of serum creatinine as biomarker of disease progression in spinal and bulbar muscular atrophy (SBMA). Scientific Reports, 2023, 13, .	3.3	1
38	Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era. Frontiers in Neurology, 0, 14, .	2.4	0
39	Whole-Body Muscle Magnetic Resonance Imaging in 81 Patients with Spinal and Bulbar Muscular Atrophy: A Prospective Study. Annals of Neurology, 2024, 95, 596-606.	5.3	0
40	A phenotypically robust model of spinal and bulbar muscular atrophy in <i>Drosophila</i> . Journal of Neuroscience Research, 2024, 102, .	2.9	0

#	ARTICLE	IF	CITATIONS
41	271st ENMC international workshop: Towards a unifying effort to fight Kennedy's disease. 20-22 October 2023, Hoofddorp, Netherlands. Neuromuscular Disorders, 2024, 38, 8-19.	0.6	0